NASDAQ:OCUL - Ocular Therapeutix Stock Price, Forecast & News

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OCUL stock has decreased by 8.0% and is now trading at $4.92. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ocular Therapeutix.

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Ocular Therapeutix.

Ocular Therapeutix Inc (NASDAQ:OCUL) released its earnings results on Thursday, March, 12th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.45) by $0.08. The biopharmaceutical company earned $2.26 million during the quarter, compared to the consensus estimate of $2.30 million. Ocular Therapeutix had a negative net margin of 2,043.34% and a negative return on equity of 801.90%. View Ocular Therapeutix's earnings history.

7 Wall Street analysts have issued twelve-month price objectives for Ocular Therapeutix's shares. Their forecasts range from $3.00 to $11.00. On average, they anticipate Ocular Therapeutix's share price to reach $7.00 in the next year. This suggests a possible upside of 42.3% from the stock's current price. View analysts' price targets for Ocular Therapeutix.

Press coverage about OCUL stock has trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ocular Therapeutix earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutOcular Therapeutix.

Ocular Therapeutix saw a drop in short interest in February. As of February 14th, there was short interest totaling 6,130,000 shares, a drop of 7.8% from the January 30th total of 6,650,000 shares. Based on an average daily volume of 639,000 shares, the short-interest ratio is currently 9.6 days. Currently, 14.7% of the shares of the company are sold short. View Ocular Therapeutix's Current Options Chain.

Some companies that are related to Ocular Therapeutix include Heron Therapeutics (HRTX), NextCure (NXTC), Esperion Therapeutics (ESPR), Opko Health (OPK), Enanta Pharmaceuticals (ENTA), Akebia Therapeutics (AKBA), Amneal Pharmaceuticals (AMRX), Revance Therapeutics (RVNC), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Aimmune Therapeutics (AIMT), Supernus Pharmaceuticals (SUPN), Odonate Therapeutics (ODT), Phibro Animal Health (PAHC) and Endo International (ENDP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Celgene (CELG), Omeros (OMER), TG Therapeutics (TGTX), Cara Therapeutics (CARA), Melinta Therapeutics (MLNT), Egalet (EGLT) and NVIDIA (NVDA).

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Ocular Therapeutix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Deltec Asset Management LLC (4.42%), Man Group plc (1.58%), State Street Corp (1.47%), Geode Capital Management LLC (1.19%), Ieq Capital LLC (0.53%) and Ieq Capital LLC (0.53%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends for Ocular Therapeutix.

OCUL stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, FMR LLC, Nuveen Asset Management LLC, Nottingham Advisors Inc., Mercer Global Advisors Inc. ADV, Goldman Sachs Group Inc., and Barclays PLC. View insider buying and selling activity for Ocular Therapeutix.

OCUL stock was purchased by a variety of institutional investors in the last quarter, including Ieq Capital LLC, Ieq Capital LLC, Deltec Asset Management LLC, Levin Capital Strategies L.P., Geode Capital Management LLC, Virtu Financial LLC, State Street Corp, and California Public Employees Retirement System. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc, Richard L Md Lindstrom, and Summer Road Llc. View insider buying and selling activity for Ocular Therapeutix.

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OCUL stock can currently be purchased for approximately $4.92.

Ocular Therapeutix has a market capitalization of $258.69 million and generates $4.23 million in revenue each year. The biopharmaceutical company earns $-86,370,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Ocular Therapeutix employs 167 workers across the globe. View additional information about Ocular Therapeutix.

The official website for Ocular Therapeutix is http://www.ocutx.com/.

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]